PMID- 25301492
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20220330
IS  - 2299-8306 (Electronic)
IS  - 0423-104X (Linking)
VI  - 65
IP  - 5
DP  - 2014
TI  - Is high dose intravenous methylprednisolone pulse therapy in patients with 
      Graves' orbitopathy safe?
PG  - 402-13
LID - 10.5603/EP.2014.0056 [doi]
AB  - High dose intravenous glucocorticoid pulse (i.v. GCS) therapy is a proven 
      approach in patients with active, moderate to severe Graves' orbitopathy (GO) and 
      dysthyroid optic neuropathy (DON). In moderate to severe GO, the European Group 
      on Graves' Orbitopathy (EUGOGO) recommends a 12-week course of intravenous 
      methylprednisolone (i.v. MP) pulse therapy with a cumulative dose of 4.5 g. The 
      response rate of i.v. GCS treatment is significantly higher than oral 
      glucocorticoid (oral GCS) therapy and is associated with fewer adverse events. 
      However, a major concern was raised because of reports of fatal side effects 
      which may be associated with this therapy, especially when single and cumulative 
      doses of methylprednisolone (MP) are higher than recommended. The prevalence and 
      severity of adverse effects during treatment have not been fully described. The 
      aim of this review was to summarise the frequency of major adverse effects of 
      i.v. GCS compared to oral GCS and attempt to propose some practical suggestions 
      as to how to monitor and prevent the development of side effects.
FAU - Miskiewicz, Piotr
AU  - Miskiewicz P
AD  - Department of Internal Medicine and Endocrinology, Medical University of Warsaw. 
      piotr.miskiewicz@wum.edu.pl.
FAU - Kryczka, Adrianna
AU  - Kryczka A
FAU - Ambroziak, Urszula
AU  - Ambroziak U
FAU - Rutkowska, Beata
AU  - Rutkowska B
FAU - Glowczynska, Renata
AU  - Glowczynska R
FAU - Opolski, Grzegorz
AU  - Opolski G
FAU - Kahaly, George
AU  - Kahaly G
FAU - Bednarczuk, Tomasz
AU  - Bednarczuk T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Endokrynol Pol
JT  - Endokrynologia Polska
JID - 0370674
RN  - 0 (Anti-Inflammatory Agents)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Administration, Intravenous
MH  - Anti-Inflammatory Agents/*administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Graves Ophthalmopathy/*drug therapy
MH  - Humans
MH  - Methylprednisolone/*administration & dosage/*adverse effects
MH  - Orbit/*drug effects/pathology
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2014/10/11 06:00
MHDA- 2016/11/01 06:00
CRDT- 2014/10/11 06:00
PHST- 2014/06/10 00:00 [received]
PHST- 2014/07/03 00:00 [accepted]
PHST- 2014/07/03 00:00 [revised]
PHST- 2014/10/11 06:00 [entrez]
PHST- 2014/10/11 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - VM/OJS/J/38564 [pii]
AID - 10.5603/EP.2014.0056 [doi]
PST - ppublish
SO  - Endokrynol Pol. 2014;65(5):402-13. doi: 10.5603/EP.2014.0056.